Joseph Gligorov, MD, recommends using tucatinib in combination with trastuzumab and capecitabine as a preferred strategy after trastuzumab deruxtecan, favoring it over another antibody-drug conjugate (ADC) due to limited data on the latter's effectiveness.
Dr Joseph Gligorov highlights the impact of trastuzumab deruxtecan in treating HER2-positive breast cancer due to its impressive results in progression-free survival and overall survival, emphasizing its importance in early treatment, while acknowledging the need to monitor safety issues.
Joseph Gligorov, MD, reviews advances in the treatment of advanced HER2+ breast cancer, shares his global perspective, and explains how ESMO and NCCN guidelines are similar.
Jane Meisel, MD, discusses managing adverse events in patients receiving second- or third-line treatments for HER2+ metastatic breast cancer, emphasizing close monitoring, patient communication, and symptom-specific interventions.
Jane Meisel, MD, elaborates on the evolution and significance of the antibody-drug conjugate trastuzumab deruxtecan in treating HER2+ metastatic breast cancer, highlighting its effectiveness and considerations for its usage.